INTRODUCTION
Treatment with tumor necrosis factor (TNF) antagonists has been recognized as a risk factor of active tuberculosis (TB) in patients with immune-mediated inflammatory diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn s disease (CD), ' psoriatic arthritis, and psoriasis.( ) Most cases of TB develop soon after treatment initiation and correspond to reactivation of a latent 1 -7 TB infection.( , ) Scientific organizations and health authorities worldwide have proposed recommendations for screening patients with 4 5 latent TB infection and treating such patients before initiating anti-TNF treatment, and the effectiveness of these recommendations has been demonstrated.( ) 8
All three available TNF antagonists have been associated with increased incidence of TB. However, a possible difference between infliximab and etanercept in incidence of TB is suspected from the spontaneous reporting of TB cases to the US Food and Drug Administration ( ) before September 2002, when no recommendations of screening for latent TB existed. In one study, the incidence of 5 TB was 28 per 100,000 patient-years for patients receiving etanercept versus 54 per 100,000 for patients receiving infliximab.( ) 9
Likewise, four registries found small differences in incidence of TB between RA patients receiving infliximab or etanercept, although not statistically significant, perhaps because in each of these registries, the number of TB cases was low (2 to 13), these registries being not powered enough to demonstrate very rare events or investigate a difference in risk depending on anti-TNF agent.( , , , ) No specific 1 2 6 7 epidemiologic data are available for adalimumab, but results of phase-3 and -4 clinical studies suggested that use of this drug may increase the risk of TB to a level close to that of infliximab ( ). 10
Thus, we used another strategy to investigate incidence of TB by setting up a national registry to collect all cases of TB occurring during 3 years in French patients receiving anti-TNF therapy, whatever the indication for use. The aim of this large prospective study was to describe cases of TB associated with anti-TNF therapy and their outcome; identify the risk factors of TB occurrence in patients receiving anti-TNF therapy, particularly the anti-TNF agent; and estimate the global and drug-specific incidence of TB after the establishment and widespread knowledge by clinicians of recommendations for TB prophylaxis before anti-TNF therapy.
Identification and validation of tuberculosis cases
To enhance exhaustiveness of the collection of cases of TB, different sources were used.
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Arthritis Rheum . Author manuscript Page / 3 14 All cases reported to the 31 French pharmaco-vigilance regional centres were collected (reporting of severe drug-related adverse events is mandatory for clinicians in France) but also cases pointed out directly to the companies commercializing anti-TNF.
In addition, physicians from all the different French hospital centres implied either in the prescription of TNF blockers (i.e.
rheumatology, internal medicine, gastroenterology and dermatology departments) and/or in the management of TB (i.e. infectious diseases centres, intensive care units, chest medicine units) were directly required to report each newly diagnosed case. A direct mail reminder 4 times a year and several communications at congresses or in specialized press encouraged them to report cases.
We obtained also cases from the Institut National de Veille Sanitaire (InVS), the French national public health surveillance system that monitors TB in France, with a mandatory clinician-and biologist-based notification system.
A detailed standardized case report form was completed for each reported case of TB (whatever the source of notification), and additional documents were collected (hospitalization summary, histological and microbiological results, and other data if necessary) to enter the validation process.
Validation of cases
Included in the RATIO registry were all cases (from all sources) with a validated diagnosis of TB according to the 10 revision of the th International Classification of Diseases (A15 A19). An expert committee involving 3 experts of TB (SB, DS, OL) validated cases by -consensus on the basis of the detailed standardized case report form and the additional documents.
Assessment of exposure to anti-TNF therapy
Infliximab has been available since 1999, etanercept since 2002 and adalimumab since 2004. For all, it is mandatory in France that the first prescription be from a hospital physician. For patients who received more than one anti-TNF agent, we considered three ways of addressing the exposure: first anti-TNF agent, last anti-TNF agent, and any use of the anti-TNF agent.
Incidence study

Incidence rate of TB
We estimated the annual incidence rate of TB in patients treated with anti-TNF therapy, adjusted for age and sex, with the French sold and the mean dosage used in each indication. These data were very consistent. We used the mean of these different estimates to derive the estimation of the number of patients receiving each anti-TNF agent that we used in the main analysis.
In addition, for sensitivity analysis, we obtained independent data from the R gime Social des Ind pendants (RSI), the French health é é insurance fund for self-employed workers, which involves 3 million enrolees (i.e., 5 of the French population representative of the whole % population) and provides claims and demographic data for use of etanercept and adalimumab.
Standardized Incidence Ratios
To assess the distribution of underlying diseases, sex and age of treated patients, we used surveys of samples of prescribing clinicians, hospital pharmacies, and nonhospital pharmacies performed by the firms, and the RSI files for the patients receiving etanercept and adalimumab.
On the basis of these data and the French annual incidence rate of TB by 10-year age and sex class from 2002 to 2006 (from the Institut National de Veille Sanitaire) ( ), we estimated the standardized incidence ratio ( ) to compare the TB risk associated with 13 14 anti-TNF treatment with that in the French population.
Risk of TB in patients receiving anti-TNF therapy
A case-control study was performed with cases from the RATIO registry.
Cases
Cases were all validated cases of TB in the registry with a labelling indication for use of anti-TNF treatment (i.e. RA, spondylarthropathy SpA; AS or psoriatic arthritis , UC or CD, or psoriasis).
[ ]
Controls
Tuberculosis complicating anti-TNF therapy Arthritis Rheum . Author manuscript Page / 4 14 Tuberculosis-free patients receiving anti-TNF treatment in a labelling indication were included from centres involved in the RATIO registry in a global pool of controls. From that pool, we randomly selected patients for a database of controls reflecting the proportion of patients receiving each of the three anti-TNF drug in France. Two controls per case were randomly matched by sex and underlying inflammatory disease from this database of controls. We also used a second sample of controls randomly selected from the same database of controls, with the same matching criteria (second matching). In addition, we used a third sample of controls (1 control per case), adding the time from onset of anti-TNF treatment as matching criteria (third matching).
Statistical analysis
The number of cases of TB in France during the study period determined the sample size. A descriptive analysis was performed for the whole sample.
Annual incidence rate of tuberculosis
The SIR was calculated for anti-TNF agent use as a whole and for agents used individually. The 95 confidence intervals (CIs) for % each SIR were calculated, and the deviation of the SIR from 1.00 was tested assuming a Poisson distribution for the observed cases because of the small number of cases.
Case-control study
We identified the risk factors for TB by both univariate and multivariate analysis (conditional logistic regression model). The Factors included in the stepwise multivariate model were those associated with the status (case or control) in univariate analysis with a significance level of p<0.20. We used the bootstrap method to examine the stability of our final model (1000 replicated bootstrap samples to find candidate variables which were more often retained). A p<0.05 was considered statistically significant.
Subgroup analyses
We performed subgroup analyses for the more frequent underlying inflammatory diseases: RA and SpA
Sensitivity analyses
To better assess the drug-specific risk, we performed sensitivity analyses for the SIR and the OR measuring the risk of adalimumab or infliximab versus etanercept, varying the definition of exposure (all anti-TNF agents, by anti-TNF agent, and for patients receiving only one anti-TNF agent, receiving anti-TNF therapy during at least 6 weeks, and currently receiving anti-TNF therapy), the different denominator estimates (denominator estimates from each of the 3 pharmaceutical firms and from the RSI), and the different criteria used for matching the controls with cases (second and third matching).
The main analyses were independently performed by two statisticians. Statistical analysis involved use of SAS release 9.1 (SAS Inst., Cary, NC).
Compliance with research ethics standards
This study authorized by the ethic committee of AP-HP, GHU Nord (Institutional Review Board of Paris North Hospitals, Paris 7
University, AP-HP; authorization number 162-08). The registry was reported at clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT00224562).
RESULTS
Description of the TB cases
We collected data on 75 cases of TB, and 69 cases were validated. Characteristics of the 69 patients with a validated TB diagnosis are in . In addition, one patient had diabetes, 3 a past history of cancer, none was HIV positive, and 1 had a chronic obstructive Table 1 pulmonary disease. For the 58 patients receiving only one anti-TNF agent, 34 (58.6 ) had received infliximab, 23 (39.7 ) adalimumab Risk 
Outcome
Three patients required hospitalization in an intensive care unit. After a median follow-up of 22.9 months, 2 patients died (one with disseminated TB died before diagnosis; another died from a cause unrelated to TB), 45 were considered cured, 5 were still receiving treatment, and in 5 TB relapsed (after a median delay of 9.4 months) (outcome was missing for 12 cases). None of the 5 patients had restarted anti-TNF therapy before relapse.
At TB diagnosis, anti-TNF therapy was not stopped in 2 patients (treated with infliximab). Moreover, anti-TNF therapy was restarted in 8 patients (etanercept in 3, infliximab in 5) after a median anti-TB treatment duration of 5.8 months (range 5 days to 10 months). No recurrence of TB was observed in these 10 patients (median follow-up 17.7 months, range 8.2 to 32.2 months).
Time occurrence of TB with anti-TNF therapy
The median time to occurrence of TB since start of anti-TNF treatment was 12.0 months. The median time since start of the last anti-TNF was 9.9 months. In 4 patients, TB had occurred despite discontinuation of anti-TNF therapy 7.1 to 13.9 months before. In these 4 patients, the anti-TNF was infliximab in 4 and adalimumab in 1.
As indicated in
, the incidence of TB was higher during the first year of anti-TNF treatment and differed depending on type of Figure 1 treatment: monoclonal antibodies (infliximab or adalimumab) or soluble receptor (etanercept).
Incidence and risk of TB for patients receiving anti-TNF therapy versus the general population
The main analysis relied on a total number of 57,711 patient-years of use of anti-TNF therapy during the 2004 2006 period, with 18 -% receiving adalimumab, 51 etanercept and 31 infliximab as the denominator of the incidence rate. The annual incidence rate of TB % % adjusted for age and sex for patients receiving anti-TNF therapy, with the French population as a reference, was 116.7 (95 CI 10.6 222.9
% -
per 100,000 patient-years). The SIR was 12.2 (9.7 15.5; p<0.0001). for adalimumab. Because the incidence rates and SIRs were close for adalimumab and infliximab and their mechanisms of action are similar, we pooled data for adalimumab and infliximab for subgroup and sensitivity analyses. Still, a difference between monoclonal-antibody and soluble-receptor anti-TNF therapy was observed in the main analysis and in the different sensitivity analyses ( ), even when we separately used the different estimates from independent sources, which gave very consistent adjusted incidence Figure 2 rates and SIRs ( ). suppl Figure 1 
Risk factors of TB for patients receiving anti-TNF therapy
The case-control study involved 68 cases (as described in the methods, the patient treated for Behcet s disease was not included in this Table 2 multivariate analysis, the following factors were predictive of TB: age, being born in an endemic area, time from onset of anti-TNF treatment, and therapy with adalimumab or infliximab versus etanercept.
Results of the main multivariate analysis are presented in . Risk of TB was higher with infliximab or adalimumab than with table 3 etanercept. (OR 13.3 (95 CI 2.6 69.0; p 0.002) and 17.1 (95 CI 3.6 80.6; p 0.0003), respectively. As for the SIRs, we pooled data for
adalimumab and infliximab for the subgroup and sensitivity analyses, for more power. The drug-specific OR were also similar with the second and third matching and in subgroup and sensitivity analysis ( ). Figure 3 
DISCUSSION
Our analysis of 69 cases of TB collected over 3 years in the RATIO registry clearly demonstrated a difference in risk of TB between patients receiving monoclonal-antibody than soluble-receptor anti-TNF therapy. We observed a 7-to 17-fold difference in risk depending on the 2 types of anti-TNF agents used, from two different methodological approaches to assess the risk of TB: a comparison of incidence rate with the French general population and a case-control study with controls receiving anti-TNF therapy for the same underlying inflammatory diseases. The risk of TB was higher during the first year of anti-TNF treatment, which favoured the reactivation of latent TB. Moreover, none of the 69 cases had been treated with correct chemoprophylaxis against TB before anti-TNF treatment was initiated.
After the FDA alert of the risk of TB associated with the use of infliximab, numerous countries set up registries to investigate the safety of anti-TNF agents. All registries of biologics but ours are cohort studies involving only a part of the population of focus and thus are not powered enough to demonstrate very rare events or investigate a difference in risk depending on anti-TNF agent used, nor are the randomized controlled trials.( ) In the cohort of the US national data bank for rheumatic diseases (NDB), the rate of TB was not 15
increased in anti-TNF-na ve RA patients (6.2 (1.6 34.4) per 100,000 patient-years) but was increased in RA patients receiving infliximab ï -(52.5 (14.3 134.4) per 100,000 patient-years)( ). However in this study, the rate was calculated from only 4 cases of TB among 6,460
patients receiving infliximab. In the same study, no case of TB was observed for 2,327 patients receiving etanercept. In the British registry, the incidence of TB was 1.5 per 1000 patient-years with infliximab and 0.5 per 1000 patient-years with etanercept, but the number of cases was 7 and 2, respectively.( ) In the Swedish registry, the incidence rates were 1.5 per 1000 patient-years with infliximab and 0.8 per 1000 2
Page / 7 14 ) the difference in reverse signalling due to a difference in membrane TNF targeting may have other consequences. For example, 24
anti-TB-specific T cells show a clear difference in effector function. Two studies provided the same results: adjunct infliximab or in vitro adalimumab treatment at therapeutic concentrations to specific human anti-TB T cells was much more efficient in decreasing proliferation Our study also confirmed that, as emphasized by others,( ) anti-TB chemoprophylactic treatment is efficient for preventing TB. None 8 of our patients with TB had received a correct prophylactic antibiotic against TB. The efficacy of screening and anti-TB chemoprophylaxis may explain why the median time from the beginning of anti-TNF therapy to TB onset is much higher (12 and 10 months for the first and the last anti-TNF, respectively) in our study than in the first study describing TB in patients treated with infliximab (14 weeks),( ) when 9 no screening for TB was recommended. However, probably we observed both features of TB infection in our study: reactivation of latent TB infection (corresponding to the high risk during the first year of anti-TNF treatment as shown in and in the case-control Figure 1 results) and new infection occurring during follow-up, which will never be avoided with pre-treatment screening.
In conclusion, our study provides clear evidence of a higher risk of TB with monoclonal-antibody anti-TNF therapy than with soluble-receptor therapy. These differences can be supported by differences of action of the 2 types of agents on membrane TNF leading to a differential effect on effector T cells and on Treg. These different mechanisms of action could also explain a better efficacy of monoclonal-antibody therapy in CD, in other granulomatous diseases such as sarcoidosis( ) and in uveitis.( ) 28 29
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Figure 1
Cumulative incidence of TB as a function of anti-TNF treatment duration as a whole and by anti-TNF agent.
Figure 2
Analysis of the estimation of the SIR for the risk of TB, whatever the anti-TNF agent, and according to the anti-TNF agent received and the underlying inflammatory disease n is the number of cases involved in the calculation (numerator of the incidence rate).The plot size relates to the number of patients treated involved in the calculation (denominator of the incidence rate).
Figure 3
Sensitivity analysis of the results of the case-control analysis odds ratios (OR) from multivariate analysis for the risk of being treated with adalimumab or infliximab rather than with etanercept. n is the number of cases involved in the calculation. The plot size relates to the number of patients treated involved in the calculation. 
